key: cord-0707134-wgs6s2vk
authors: Zhu, Guoliang; Zhu, Chunmei; Zhu, Yun; Sun, Fei
title: Minireview of progress in the structural study of SARS-CoV-2 proteins
date: 2020-06-29
journal: Current research in microbial sciences
DOI: 10.1016/j.crmicr.2020.06.003
sha: a9a11559d8f8a9af8ab2d880e1e4c7b4c15ac6b0
doc_id: 707134
cord_uid: wgs6s2vk

Abstract A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization, broke out in China and rapidly developed into a global pandemic, with millions of cases and hundreds of thousands of deaths reported globally. The novel coronavirus, which was designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the etiological agent of COVID-19. On the basis of experience accumulated following previous SARS-CoV and MERS-CoV outbreaks and research, a series of studies have been conducted rapidly, and major progress has been achieved with regard to the understanding of the phylogeny and genomic organization of SARS-CoV-2 in addition its molecular mechanisms of infection and replication. In the present review, we summarized crucial developments in the elucidation of the structure and function of key SARS-CoV-2 proteins, especially the main protease, RNA-dependent RNA polymerase, spike glycoprotein, and nucleocapsid protein. Results of studies on their associated inhibitors and drugs have also been highlighted.

In December 2019, a novel pneumonia named coronavirus disease 2019 , emerged in Wuhan, China [1, 2] . Its symptoms included dry cough, fever, headache, dyspnea, and pneumonia [3] [4] [5] . Due to the high contagiousness and transmission rate of the virus during the presymptomatic phase [6, 7] , COVID-19 became a pandemic and spread to more than 212 countries and territories, and community transmission took place in many countries including the United States, Germany, France, Spain, Japan, Singapore, South Korea, Iran, and Italy. Thus far, millions of cases and hundreds of thousands of deaths have been recorded, with rapidly increasing numbers globally.

A previously unknown coronavirus, designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to β-coronaviruses and has a genomic sequence closely related to that of SARS-CoV, was determined as the etiological agent of this severe infection [1, [8] [9] [10] . The Coronaviridae family includes two subfamilies: Letovirinae and Orthocoronavirinae, and the Orthocoronavirinae family consists of the α-coronavirus, β-coronavirus, γ -coronavirus, and δ-coronavirus genera [11] . Many β-coronaviruses are human pathogens and cause severe respiratory diseases, including SARS-CoV, the Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), and currently, SARS-CoV-2. Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses with mammalian and avian hosts. The length of the SARS-CoV-2 genome is approximately 30kb [9] , and it encodes at least 29 proteins, including 16 non-structural proteins (NSP), 4 structural proteins, and 9 accessory proteins ( Figure 1 ).

Upon cell entry, the genomic RNA of SARS-CoV-2 is translated to produce two overlapping polyproteins, pp1a and pp1ab, from two open reading frames (ORFs), ORF1a and ORF1b, respectively. Subsequently, pp1ab is cleaved into 16 NSPs by viral proteases NSP3 and NSP5, which harbor a papain-like protease domain and a 3C-like protease domain, respectively ( Figure 1 ). The NSP12 (also known as the RNA-dependent RNA polymerase, RdRp) is the central component of the replication/transcription machinery in the synthesis of viral RNA, with the assistance of NSP7 and NSP8 as cofactors [3, 12] . SARS-CoV-2, as a positive-sense, single-stranded RNA virus, has the capacity to synthesize full-length negative-sense RNA chain, which serve as templates for further generation of positive-sense genomic RNA (gRNA) and subgenomic RNAs (sgRNAs). The gRNA is enveloped by structural proteins for progeny virion assembly, whereas the sgRNAs are relatively short and encode conserved structural proteins (spike [S] glycoprotein, envelope [E] protein, membrane [M] protein, and nucleocapsid [N] protein), and several accessory proteins. The nine accessory proteins (3a, 3b, 6, 7a, 7b, 8, 9b, 9c, and 10) of SARS-CoV-2 participate in various processes, ranging from coronavirus replication to resistance against immune responses ( Figure 1 ) [10, 13] .

Elucidating the structural and functional features of the major proteins encoded by the SARS-CoV-2 genome would facilitate the development of viral specific drug therapies and vaccines to combat the global pandemic. With the tireless efforts of researchers, the atomic resolution structure of some key SARS-CoV-2 proteins have been resolved using cryo-Electron Microscopy (cryo-EM) or X-ray methods (Table   1) , and their corresponding biological functions have been reported, promoting the rapid discovery of antiviral agents with clinical potential. The present review summarizes current research findings and developments with regard to the structure and function of major proteins encoded by SARS-CoV-2, and the insights could promote drug and vaccine development for the treatment and management of COVID-19.

The functional polyproteins of SARS-CoV-2, pp1a and pp1ab, are cleaved into 16 NSPs, mainly by a 33.8-kDa main protease (M pro ), which is also referred to as 3C-like protease (3CL pro ) [14, 15] . There are at least 11 conserved M pro restriction sites on the pp1ab protein, starting with its autolytic cleavage site [16] . Because M pro has no closely related homologues in humans, its specific inhibitor has been demonstrated to inhibit viral life cycle with no obvious biotoxicity [17] [18] [19] [20] . Consequently, extensive studies on the structure of SARS-CoV-2 M pro have been conducted rapidly following the COVID-19 outbreak [21, 22] . Jin et al., for the first time, reported the crystal structure of full-length SARS-CoV-2 M pro in complex with N3 based on 2.1 Å X-ray diffraction data [23] . Almost at the same time, Zhang et al., determined the X-ray structures of the wild type SARS-CoV-2 M pro protein at 1.75 Å, in addition to the structures of several inhibitor-bound M pro proteins (Table 1 ) [24] .

All the aforementioned atomic structures of SARS-CoV-2 M pro proteins are almost identical and highly similar to other M pro proteins resolved previously [25] [26] [27] [28] , which suggests that the conserved protein is essential for the coronavirus family. Its overall structure is a dimer with a crystallographic 2-fold symmetry axis. Each protomer consists of three domains, Domains I (residues 8-101), II (residues and III (residues 201-303), and a long loop region (residues 185-200) connects domains II and III ( Figure 2 ). The chymotrypsin-like and picornavirus 3C protease-like Domains I and II both form an antiparallel β-barrel structure, and the substrate-binding site is located in a cleft between them. Domain III is composed of five α-helices arranged into a largely antiparallel globular cluster, which forms a salt-bridge interaction between Glu290 of one monomer and Arg4 of the other monomer to mediate dimerization of the M pro [29] . In addition, the dimer interface predominantly involves interactions between domain II of one protomer and the N-terminal residues of the other, which could facilitate the shaping of the substrate-binding pocket of M pro protein ( Figure 2 ). SARS-CoV-2 M pro is an attractive and key target for antiviral reagent discovery.

Several compounds that inhibit M pro activity have been identified through a combination of structure-based virtual screening and high-throughput screening. For example, Wu et al., discovered a series of clinical drugs and natural products with antiviral, antibacterial, and anti-inflammatory activities that showed high affinity to SARS-CoV-2 M pro by artificial intelligence-assisted computer virtual screening [30] .

As reported previously, N3 could specifically inhibit multiple CoV M pro s, including those from SARS-CoV and MERS-CoV [20, 25, 27, 28] . Jin et al., resolved the crystal structure of SARS-CoV-2 M pro in complex with N3 and demonstrated that N3 was a potent irreversible inhibitor of SARS-CoV-2 M pro . Subsequently, using structure-based virtual and high-throughput screening, they identified six promising antiviral compounds out of over 10,000 compounds, including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as M pro inhibitors [31] . Zhang et al., presented the crystal structure of SARS-CoV-2 M pro in complex with an α-ketoamide inhibitor and developed the lead compound into a potent inhibitor based on the structure, which displayed obvious lung tropism and suitability for inhalation [24] . In addition, Dai et al., designed and synthesized two peptide-like compounds (11a and 11b) that exhibited high inhibitory activity against SARS-CoV-2 M pro and viral infection. More importantly, both compounds showed better PK properties and lower toxicity in vivo, suggesting that they are promising drug candidates. Furthermore 1.5 Å high-resolution structures of SARS-CoV-2 M pro in complex with 11a or 11b, revealed the precise interaction and molecular mechanism between M pro and compounds [32] .

Coronavirus employs a multi-subunit replication/transcription machinery of viral NSPs to synthesize viral RNA [33] . The RNA-dependent RNA polymerase (RdRp, or NSP12) is the core component and plays a central role in SARS-CoV-2 replication and transcription cycle [34, 35] . NSP7 and NSP8 increase RdRp activity in template-prime binding and processivity as accessary factors [12, 36] . Therefore, RdRp is considered as the primary target for nucleotide analog antiviral inhibitors such as remdesivir [37] [38] [39] , whose triphosphate form (RTP) is the active drug within cells [40] , and shows the potential for use in COVID-19 therapy. Therefore, determining the three-dimensional structures of SARS-CoV-2 RdRp with RNA template or inhibitors can provide a basis for the design of novel antiviral therapeutics (Table 1) .

Gao et al., for the first time, reported the high-resolution cryo-EM structure of SARS-CoV-2 full-length NSP12 (residues 1-932) in complex with NSP7 (residues 1-83) and NSP8 (residues 1-198) cofactors at 2.9 Å [41] . It comprises one NSP12 monomer, one NSP8 monomer and one NSP7-NSP8 pair, similar to SARS-CoV RdRp complex [36] . The structure of the SARS-CoV-2 NSP12 has three domains: a (Table 1 ). One is in apo form, at a resolution of 2.8 Å, and the other is in binding of a 50-base template-primer RNA and the monophosphate form of remdesivir (RMP) at a resolution of 2.5 Å [44] . The overall structures of the two RdRp structures are highly similar to NSP12-NSP7-NSP8 complex solved by Gao et al. [41] . In template-RMP RdRp complex, extensive protein-RNA interactions between the template-primer RNA and NSP12 were revealed, which explicates how the RdRp complex recognizes RNA rather than DNA, and suggests no sequence-specific RNA binding. RMP is covalently incorporated at the 3" end of the primer strand and harbors the center of the catalytic active site, with extensive hydrogen bond networks. Two magnesium ions near the bound RMP form an active catalytic site. A pyrophosphate occupies the nucleotide entrance, which could make the active site inaccessible to nucleotide triphosphate (NTP) and in turn terminate replication process. In addition, Wang et al., reported near atomic-resolution structures of stalled pre-/post-translocated polymerase complexes, which revealed the molecular mechanism of SARS-CoV-2 RNA replication and its inhibition by remdesivir [45] .

SARS-CoV-2 enters host cells mainly through the envelope-located trimeric spike (S) glycoprotein. S protein is translated as a large polypeptide, which is subsequently cleaved by host proteases to produce two functional subunits responsible for binding to the host cell receptor (N-terminal S1 subunit) and fusion of the viral and cellular membranes (C-terminal S2 subunit) [46] [47] [48] . The receptor-binding domain (RBD) is located in the S1 subunit and can recognize human ACE2 receptor on target cell membranes ( Figure 1 and Figure 2 ). In the pre-fusion state, the S1 subunit stabilizes the entire S protein trimer and protects the S2 protein from undergoing conformational change in advance. The S2 subunit contains a hydrophobic fusion peptide and two heptad repeat regions, which could form a six-helical bundle to mediate viral entry through fusion pores (Figure 2 ). The S protein is a key target for vaccines, inhibitors, neutralizing antibodies, and diagnostics, considering its indispensable function. In the infection process of CoVs, S is further cleaved by proteases [49, 50] ; however, the cleaved S proteins always remain non-covalently associated in the metastable pre-fusion conformation [51] [52] [53] [54] [55] [56] [57] .

Such cleavage has been proposed to activate the protein for membrane fusion via extensive irreversible conformational changes [48, 51, 58] . The entry into host cells of CoVs is very complicated that requires the concerted action of receptor-binding and proteolytic processing of the S protein to promote virus-cell fusion.

The single-particle cryo-EM structure of the SARS-CoV-2 spike trimer has recently been reported in two independent studies (Table 1) [59, 60] , both of which have demonstrated that the RBD can undergo a hinge-like conformational movement to shift between "up" or "down" states, as in other coronaviruses [61] [62] [63] [64] . The "down" conformation corresponds to the receptor-inaccessible state (hide), and the "up" conformation corresponds to a receptor accessible state (expose). Wrapp et al., for the first time, reported a 3.5 Å resolution cryo-EM structure of the SARS-CoV-2 S asymmetrical trimer, in which a single RBD is observed in the "up" conformation and two other RBDs are observed in the "down" conformation [59] . The major difference between the two states is the distinct organization of the RBD within the S1 apex.

Using the 3D variability feature in cryoSPARC v2 [65] , it is observed that RBD underwent a hinge-like conformational movement that transiently hide or expose the determinants of receptor binding, much like the breathing of S1 subunits.

Walls et al., also presented an asymmetric reconstruction of the trimer with a single S domain opened (the "up" conformation) at 3.2 Å resolution, and determined the closed (all "down" conformations) SARS-CoV-2 S ectodomain trimer at 2.8 Å resolution (applying 3-fold symmetry; Table 1 ) [59] . Overall, in the "down" conformation, the SARS-CoV-2 S ectodomain is a 160 Å-long trimer with a triangular cross-section and the S1 subunit has a V-shaped architecture, resembling those of closely related β-coronaviruses, such as SARS-CoV S (Figure 2 ).

During SARS-CoV infection, the RBD domain in its S protein has a core and a receptor-binding motif (RBM), which could directly bind to the peptidase domain (PD) of the angiotensin-converting enzyme 2 (ACE2), a type I membrane protein expressed in the lungs, heart, kidney, and intestine ( Figure 2 ) [66] [67] [68] [69] . Afterward, the S2 subunit is exposed and undergoes a conformational change from a pre-fusion to a post-fusion state. Therefore, binding to the ACE2 receptor is essential for viral infection [51, 70] . Recent studies have demonstrated that SARS-CoV-2 S and SARS-CoV S share the same functional host cell receptor ACE2 [71] [72] [73] ; however, the SARS-CoV-2 RBD has a significantly higher ACE2-binding affinity than SARS-CoV RBD, based on biochemical data [60, 74] . determined the crystal structure of CR3022 in complex with the SARS-CoV-2 RBD at 3.1 Å, and they observed that CR3022 targets a highly conserved epitope away from the ACE2-binding site (Figure 2 ). Structural modeling further demonstrates that the epitope of CR3022 is only accessible when at least two RBD on the trimeric S protein are in the "up" conformation and slightly rotated so that all clashes can be avoided [78] .

Proteins that interact with SARS-CoV-2 S are also important targets for the design of novel antiviral therapies. Endosomal cysteine proteases-cathepsin B and L (CatB/L) [70] and serine protease TMPRSS2 [79] [80] [81] can be used for SARS-CoV S priming in cell lines. However, only TMPRSS2 activity is essential for viral entry into primary target cells and for viral spread in infected hosts, whereas CatB/L activity is dispensable [82] [83] [84] [85] . Hoffmann et al., demonstrate that the SARS-CoV-2 S protein is primed by TMPRSS2, and camostat mesylate, a TMPRSS2 inhibitor, could block the infection of lung cells with SARS-CoV-2 and is a potential treatment option ( Figure   2 ) [86] . Recently, it has been demonstrated that recombinant soluble human ACE2 (hrsACE2) can block the early stages of SARS-CoV-2 infection significantly.

Clinical-grade hrsACE2 can reduce SARS-CoV-2 recovery from Vero cells by a factor of 1000-5000, and block SARS-CoV-2 infections in engineered human blood vessel organoids and human kidney organoids [87] .

After the binding of the S1 subunit to the ACE2 receptor, the S2 subunit undergoes conformational changes to insert the hydrophobic fusion peptide into the host target cell membrane. The heptad repeat 1 (HR1) domain in the S2 subunit forms a homotrimer, which exposes three highly conserved hydrophobic grooves on the surface that binds the heptad repeat 2 (HR2) domain in the S2 subunit; therefore, HR1 and HR2 domains interact to form a stable six-helix bundle (6-HB) fusion core. The 6-HB fusion core structure helps bring the viral and cellular membranes into close proximity for membrane fusion and viral infection [88] . SARS-CoV-2 and SARS-CoV S2 subunits share high sequence similarities, with 92.6% and 100% overall identities in HR1 and HR2 domains, respectively. Xia et al., found that HR1and HR2 domains in SARS-CoV-2 can interact to form 6-HB [88] , and they resolved the X-ray crystal structure of SARS-CoV-2"s 6-HB [89] . The overall 6-HB structure of SARS-CoV-2 is similar to that of SARS-CoV [90] . Although the amino acid sequences of the HR2 domain from SARS-CoV-2 and SARS-CoV are identical, the HR1 domain has eight different residues, which may enhance HR1 and HR2

interactions and stabilize 6-HB conformation.

Over the past few decades, the viral HR1 domain in the S2 subunit has been EK1C4 has also showed broad-spectrum inhibitory activity against infection of SARS-CoV, MERS-CoV and other HCoVs, suggesting EK1C4 can be used for the prevention and treatment of SARSr-CoVs infection [89] .

The nucleocapsid (N) protein of coronavirus is a multifunctional RNA-binding protein and forms a helical filament structure that is required for the assembly of viral genomic RNA into a ribonucleoprotein complex. The packaging of the viral genomic RNA regulates viral replication/transcription and modulates infectious cell metabolism [93] [94] [95] [96] [97] . The N protein of SARS-CoV-2 is highly expressed and induces early antibody responses in infected patients, similar to in the case of SARS-CoV N protein [98] [99] [100] [101] Table 1 ). The overall structure is a "right-hand shape" composed of a β-hairpin, a β-sheet core and a long-loop region, which resembles a protruded basic finger, a basic palm, and an acidic wrist. The β-sheet core contains five antiparallel β-strands with a short α-helix and the long β-hairpin is a large protruding loop between β2 and β5 ( Figure 2 ). The N2b domain mediates self-association into a dimer, which subsequently assembles into a higher-order helical filament, potentially involving cooperative interactions. Ye et al., reported two crystal structures of the SARS-CoV-2 N2b domain, exhibiting a tightly intertwined dimer that is similar to that of SARS-CoV (Table 1) [107] [108] [109] [110] . The dimer interface consists of two β-strands and a short α-helix from each protomer that extend toward the opposite protomer and pack against its hydrophobic core (Figure 2 ). In addition, a combination of multi-angle light scattering and hydrogen-deuterium exchange mass spectrometry techniques has been used to explore the self-assembly mechanism of the SARS-CoV-2 nucleocapsid. Such studies enable researchers to identify small molecules that could inhibit nucleocapsid self-assembly processes, and in turn minimize the infection severity and pathogenic infectivity.

Following the COVID-19 outbreak, SARS-CoV-2 was rapidly identified as the etiological agent. Although our understanding of coronaviruses has improved substantially following previous SARS-CoV and MERS-CoV outbreaks, in 2003 and 2012, respectively, effective antiviral drugs for SARS-CoV-2 treatment and vaccines for its prevention remain unavailable. Extensive studies on the structures and functions of the major proteins involved in SARS-CoV-2 has been conducted, which have enhanced our general understanding of the mechanisms of its infection and replication. Furthermore, combined with structure-based predictions, experiments at cellular and animal levels in addition to high-throughput screening activities have revealed numerous compounds, including clinical drugs, drug candidates, and other pharmacologically active compounds, to be inhibitors of viral key proteins; these are potential antiviral drugs for the treatment of COVID-19 disease.

The atomic structures of SARS-CoV-2 proteins not only help to research and develop antiviral drugs, but also provide important basis for vaccine design. Among four major structural proteins, the S glycoprotein plays crucial roles in viral entry and pathogenesis, which is a key target for vaccines, but it is highly glycosylated and antigenically variable. 20 N-linked glycosylation sequons per protomer are conserved among SARS-CoV-2 S and SARS-CoV S [59] , and these oligosaccharides might modulate antibody recognition in SARS-CoV [62, 111] . Consequently, the precise structure of the S glycoprotein and the organization of these N-Linked Glycans will provide atomic-level information to help the design and development of vaccines. At present, multiple SARS-CoV-2 vaccine types are under development, including inactivated or weakened vaccines, viral vectored vaccines, DNA-or RNA-based vaccines, adenovirus-based vaccines and protein-based vaccines, which are based on the S antigen [112] [113] [114] . 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

A Novel Coronavirus from Patients with Pneumonia in China

SARS-CoV-2 is an appropriate name for the new coronavirus

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (2020)

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China

Coronaviridae Study Group of the International Committee on Taxonomy of V: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A new coronavirus associated with human respiratory disease in China

Origin and evolution of pathogenic coronaviruses

One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities

The Architecture of SARS-CoV-2 Transcriptome

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

Conservation of substrate specificities among coronavirus main proteases

An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers

Correction: Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease

pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses

Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design. Sci Rep

Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design

The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

The coronavirus replicase

Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates

The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

First Case of 2019 Novel Coronavirus in the United States

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

RNA synthetic mechanisms employed by diverse families of RNA viruses

Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Structural basis for RNA replication by the SARS-CoV-2 polymerase

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex

Structure, Function, and Evolution of Coronavirus Spike Proteins

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion

Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide

Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner

Pre-fusion structure of a human coronavirus spike protein

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism

Structural insights into coronavirus entry

Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer

Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence

Veesler D: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell (2020)

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

The 3.1-Angstrom Cryo-electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structural basis of receptor recognition by SARS-CoV-2

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2

A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry

TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection

Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry

Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry

Protease inhibitors targeting coronavirus and filovirus entry

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle

Background paper. Functions of the coronavirus nucleocapsid protein

The coronavirus nucleocapsid is a multifunctional protein

High affinity interaction between nucleocapsid protein and leader/intergenic sequence of mouse hepatitis virus RNA

Specific interaction between coronavirus leader RNA and nucleocapsid protein

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

Characterization and application of monoclonal antibodies against N protein of SARS-coronavirus

Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients

Coronavirus N protein N-terminal domain (NTD) specifically binds the transcriptional regulatory sequence (TRS) and melts TRS-cTRS RNA duplexes

Functional transcriptional regulatory sequence (TRS) RNA binding and helix destabilizing determinants of murine hepatitis virus (MHV) nucleocapsid (N) protein

Ribonucleocapsid formation of severe acute respiratory syndrome coronavirus through molecular action of the N-terminal domain of N protein

Amino acid residues critical for RNA-binding in the N-terminal domain of the nucleocapsid protein are essential determinants for the infectivity of coronavirus in cultured cells

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

Structure of the SARS coronavirus nucleocapsid protein RNA-binding dimerization domain suggests a mechanism for helical packaging of viral RNA

Solution structure of the c-terminal dimerization domain of SARS coronavirus nucleocapsid protein solved by the SAIL-NMR method

Crystal structure of the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein dimerization domain reveals evolutionary linkage between corona-and arteriviridae

Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

The race for coronavirus vaccines: a graphical guide

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

Progress and Concept for COVID-19 Vaccine Development

We thank Ping Shan and Ruigang Su (F.S. lab) for their assistance in lab management. This work was supported by grants from National Natural Science

Program of China (2017YFA0504700 and 2018YFA0901102).

and 621-679 aa), the palm subdomain (582-620 and 680-815 aa), and the thumb subdomain (816-920 aa). S glycoprotein is divided into two subunits by protease at the S1/S2 protease cleavage site, Its S1 subunit contains NTD (14-305 aa), RBD (319 -541 aa), and RBM (437-508 aa). Its S2 subunit contains FP (788-806 aa), HR1